• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/12/21 6:42:00 AM ET
    $CEMI
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $CEMI alert in real time by email
    SC 13G/A 1 tm216457d4_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

    CHEMBIO DIAGNOSTICS, INC.

    (Name of Issuer)

     

    Common Stock, $0.01 par value

    (Title of Class of Securities)

     

    163572209

    (CUSIP Number)

     

    December 31, 2020

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x  Rule 13d-1(b)
    ¨  Rule 13d-1(c)
    ¨  Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    Continued on following pages

    Page 1 of 7 Pages

     

     

     

     

     

     

    CUSIP NO.  163572209 Page 2 of 7 Pages

     

    CUSIP No.  163572209
    (1) Names of reporting persons Nantahala Capital Management, LLC
    (2) Check the appropriate box if a member of a group (a)
    (see instructions) (b)
    (3) SEC use only  
    (4) Citizenship or place of organization MA
    Number of shares beneficially owned by each reporting person with:  
    (5) Sole voting power 0
    (6) Shared voting power 0
    (7) Sole dispositive power 0
    (8) Shared dispositive power 0
    (9) Aggregate amount beneficially owned by each reporting person 0
    (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions)  
    (11) Percent of class represented by amount in Row (9) 0%
    (12) Type of reporting person (see instructions) IA

     

     

     

     

    CUSIP NO.  163572209 Page 3 of 7 Pages

     

    CUSIP No.  30162V102
    (1) Names of reporting persons Wilmot B. Harkey
    (2) Check the appropriate box if a member of a group (a)
    (see instructions) (b)
    (3) SEC use only  
    (4) Citizenship or place of organization USA
    Number of shares beneficially owned by each reporting person with:  
    (5) Sole voting power 0
    (6) Shared voting power 0
    (7) Sole dispositive power 0
    (8) Shared dispositive power 0
    (9) Aggregate amount beneficially owned by each reporting person 0
    (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions)  
    (11) Percent of class represented by amount in Row (9) 0%
    (12) Type of reporting person (see instructions) HC

     

     

     

     

    CUSIP NO.  163572209 Page 4 of 7 Pages

     

    CUSIP No.  30162V102
    (1) Names of reporting persons Daniel Mack
    (2) Check the appropriate box if a member of a group (a)
    (see instructions) (b)
    (3) SEC use only  
    (4) Citizenship or place of organization USA
    Number of shares beneficially owned by each reporting person with:  
    (5) Sole voting power 0
    (6) Shared voting power 0
    (7) Sole dispositive power 0
    (8) Shared dispositive power 0
    (9) Aggregate amount beneficially owned by each reporting person 0
    (10) Check if the aggregate amount in Row (9) excludes certain shares (see instructions)  
    (11) Percent of class represented by amount in Row (9) 0%
    (12) Type of reporting person (see instructions) HC

     

    Item 1(a). Name of Issuer:
       
      CHEMBIO DIAGNOSTICS, INC. (the “Issuer”).
       
    Item 1(b). Address of the Issuer's Principal Executive Offices:
       
      555 Wireless Blvd. Hauppauge, NY 11788
       
    Item 2(a). Name of Person Filing
       
     

    Nantahala Capital Management, LLC (“Nantahala”)

    Wilmot B. Harkey

    Daniel Mack (together the “Reporting Persons”)

       
    Item 2(b). Address of Principal Business Office or, if None, Residence:
       
     

    130 Main St. 2nd Floor

    New Canaan, CT 06840

     

    Item 2(c). Citizenship:
       
     

    Nantahala is a Massachusetts limited liability company.

    Each of Messrs. Harkey and Mack is a citizen of the United States of America.

       
    Item 2(d).

    Title of Class of Securities:

     

     

    Common Stock, $0.01 par value (the “Shares”).

     

     

     

     

    CUSIP NO.  163572209 Page 5 of 7 Pages

     

    Item 2(e). CUSIP Number:
     

     

    163572209

     


    Item 3.

    If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

     

     

    (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     

    (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     

    (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).

     

    (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).

     

    (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

     

    (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).

     

    (g) x A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G).

     

    (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).

     

    (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the

    Investment Company Act of 1940 (15 U.S.C. 80a-3).

     

    (j) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(J).

     

    Item 4.

     

    Ownership:

       
    Item 4(a).

    Amount Beneficially Owned:

     

    As of December 31, 2020, Nantahala may be deemed to be the beneficial owner of 0 Shares held by funds and separately managed accounts under its control, and as the managing members of Nantahala, each of Messrs. Harkey and Mack may be deemed to be a beneficial owner of those Shares.

     

       
    Item 4(b).

    Percent of Class:

     

    As of December 31, 2019, each of the Reporting Persons may be deemed to be the beneficial owner of 0% of the total number of Shares outstanding.

     

     

     

     

    CUSIP NO.  163572209 Page 6 of 7 Pages

     

    Item 4(c). Number of shares as to which such person has:
       
     

    Nantahala Capital Management, LLC

     

      (i) Sole power to vote or direct the vote 0
      (ii) Shared power to vote or to direct the vote 0
      (iii) Sole power to dispose or to direct the disposition of 0

     

    (iv) Shared power to dispose or to direct the disposition of 0

     

     

     

    Each of Messrs. Harkey and Mack:

     

      (i) Sole power to vote or direct the vote 0
      (ii) Shared power to vote or to direct the vote 0
      (iii) Sole power to dispose or to direct the disposition of 0
      (iv) Shared power to dispose or to direct the disposition of 0

     

    Item 5. Ownership of Five Percent or Less of a Class:
       
     

    The Reporting Persons have ceased to be beneficial owners of more than five percent of the Common Stock.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person:
       
      This Item 6 is not applicable.
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company:
       
      Each of Messrs. Harkey and Mack is filing this Schedule 13G as a control person in respect of shares beneficially owned by Nantahala, an investment adviser as described in §240.13d-1(b)(1)(ii)(E).  See Item 4(a).
       
    Item 8. Identification and Classification of Members of the Group:
       
      This Item 8 is not applicable.
       
    Item 9. Notice of Dissolution of Group:
       
      This Item 9 is not applicable.
       
    Item 10. Certification:
       
     

    By signing below each Reporting Person certifies that, to the best of such person's knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.

     

     

     

     

    CUSIP NO.  163572209 Page 7 of 7 Pages

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete, and correct.

     

    Date:  February 12, 2021 NANTAHALA CAPITAL MANAGEMENT, LLC 
         
      By:  /s/ Paul E. Rehm
        Paul E. Rehm
        Chief Compliance Officer
         
       /s/ Wilmot B. Harkey 
      Wilmot B. Harkey 
         
      /s/ Daniel Mack 
      Daniel Mack 

     

     

     

    Get the next $CEMI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CEMI

    DatePrice TargetRatingAnalyst
    7/22/2021Buy → Neutral
    Colliers Securities
    More analyst ratings

    $CEMI
    Leadership Updates

    Live Leadership Updates

    See more
    • Chembio Diagnostics Announces Appointment of Larry Steenvoorden as Chief Financial Officer

      HAUPPAUGE, N.Y., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today announced the appointment of Larry Steenvoorden as Chief Financial Officer effective immediately. "We are thrilled to welcome Larry to the Chembio executive leadership team. Larry has developed valuable insights over his 25 years of financial leadership experience, spanning accounting, budgeting, public company reporting, business development, and commercial strategy. Those skills will be critical to our success as we scale our business in support of our corporate growth and operational objectives," said Richard Eber

      1/5/22 4:05:00 PM ET
      $CEMI
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Innovations in Disinfection Technology Aid the Return of Workers

      NEW YORK, Dec. 9, 2020 /PRNewswire/ -- The current pandemic has been devastating for the global economy and has caused severe backlogs in hospitals. Additionally, a spike in demand for Personal Protective Equipment (PPE) and new disinfecting technologies has also been seen. For example, when it comes for PPE, the global market was valued at USD 52.7 Billion in 2019 and is expected to reach USD 92.5 Billion by 2025 while growing at a CAGR of 8.7% during 2020-2025, according to VynZ Research. As for new technologies for disinfection, a recent example comes from LG Electronics, which announced on Wednesday the launch of a disinfection robot that will assist in containing the spread of the vi

      12/9/20 9:00:00 AM ET
      $NBY
      $CEMI
      $BSGM
      $DVAX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Biotechnology: Electromedical & Electrotherapeutic Apparatus

    $CEMI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Biosynex Completes Acquisition of Chembio Diagnostics, Inc.

      Chembio Diagnostics, Inc. becomes the first North American structure controlled by Biosynex in North America STRASBOURG, France, April 27, 2023 (GLOBE NEWSWIRE) -- Biosynex SA ("Biosynex") (EPA: ALBIO), a French market leader specializing in the design and distribution of rapid tests, today announced it has completed its acquisition of Chembio Diagnostics, Inc. ("Chembio"), a leading point-of-care diagnostics company focused on infectious diseases. Chembio is now part of Biosynex Group. The complementary nature of the technologies and product portfolio as well as the combination of market opportunities will be important growth drivers for the combined company. In addition, significant ope

      4/27/23 4:30:00 PM ET
      $CEMI
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Chembio Stockholders Urged to Tender Shares Before 6:00 P.M., New York City Time, on April 26, 2023

      MEDFORD, N.Y., April 19, 2023 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (NASDAQ:CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today released the following letter to stockholders concerning the pending tender offer by Biosynex SA. April 19, 2023 Fellow Chembio Stockholders, We strongly urge you to tender your shares of common stock of Chembio Diagnostics Inc. ("Chembio") in the tender offer being made by Biosynex SA ("Biosynex") and its affiliates. The tender offer is the first step in a proposed merger between Chembio and Biosynex. Biosynex has agreed to pay $0.45 per share in cash to each of our stockholders who tender their shares prior t

      4/19/23 8:00:00 AM ET
      $CEMI
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Biosynex Extends Tender Offer for the shares of Chembio Diagnostics, Inc.

      STRASBOURG, France, April 13, 2023 (GLOBE NEWSWIRE) -- Biosynex SA ("Biosynex") (EPA: ALBIO), a French market leader specializing in the design and distribution of rapid tests, today announced that Project Merci Merger Sub, Inc. ("Purchaser"), a Nevada corporation and its wholly-owned indirect subsidiary, has extended the expiration time for the previously announced tender offer to purchase all of the issued and outstanding shares of common stock (the "Shares") of Chembio Diagnostics, Inc. (NASDAQ:CEMI) ("Chembio") at a price of $0.45 per Share, net to the seller in cash, without interest and subject to any required tax withholding, until 6:00 p.m., New York City time on April 26, 2023, un

      4/13/23 7:00:00 AM ET
      $CEMI
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $CEMI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Chembio Diagnostics downgraded by Colliers Securities

      Colliers Securities downgraded Chembio Diagnostics from Buy to Neutral

      7/22/21 7:27:54 AM ET
      $CEMI
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Colliers Securities resumed coverage on Chembio Diagnostics with a new price target

      Colliers Securities resumed coverage of Chembio Diagnostics with a rating of Buy and set a new price target of $8.00

      3/11/21 4:06:26 AM ET
      $CEMI
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $CEMI
    Financials

    Live finance-specific insights

    See more
    • Biosynex Completes Acquisition of Chembio Diagnostics, Inc.

      Chembio Diagnostics, Inc. becomes the first North American structure controlled by Biosynex in North America STRASBOURG, France, April 27, 2023 (GLOBE NEWSWIRE) -- Biosynex SA ("Biosynex") (EPA: ALBIO), a French market leader specializing in the design and distribution of rapid tests, today announced it has completed its acquisition of Chembio Diagnostics, Inc. ("Chembio"), a leading point-of-care diagnostics company focused on infectious diseases. Chembio is now part of Biosynex Group. The complementary nature of the technologies and product portfolio as well as the combination of market opportunities will be important growth drivers for the combined company. In addition, significant ope

      4/27/23 4:30:00 PM ET
      $CEMI
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Chembio Diagnostics Reports Third Quarter 2022 Financial Results

      HAUPPAUGE, N.Y., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. ("Chembio" or the "Company") (NASDAQ:CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results for the quarter ended September 30, 2022. Recent Highlights Achieved third quarter 2022 total revenue of $11.2 million including product revenue of $10.8 million, representing product revenue growth of 16% compared to the prior year periodU.S. product revenue of $4.8 million grew 361% compared to the prior year periodAwarded $3.2 million contract from the CDC for development and clinical validation of Dual-Path Platform (DPP) Syphilis Treponemal Nontreponemal (

      11/3/22 4:05:00 PM ET
      $CEMI
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Chembio Diagnostics to Report Third Quarter 2022 Financial Results on November 3, 2022

      HAUPPAUGE, N.Y., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (NASDAQ:CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will release financial results for the third quarter of 2022 after the close of trading on Thursday, November 3, 2022. The company's management team will host a corresponding conference call beginning at 4:30 p.m. Eastern Time on November 3, 2022. Investors interested in listening to the conference call may do so by dialing 888-506-0062 from the US or 973-528-0011 from outside the US and providing Entry Code: 600643 or by accessing www.chembio.com/investors/calendar-of-events/. A replay of the call

      10/20/22 4:05:00 PM ET
      $CEMI
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $CEMI
    SEC Filings

    See more
    • SEC Form 15-12G filed by Chembio Diagnostics Inc.

      15-12G - CHEMBIO DIAGNOSTICS, INC. (0001092662) (Filer)

      5/8/23 9:26:46 PM ET
      $CEMI
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form EFFECT filed by Chembio Diagnostics Inc.

      EFFECT - CHEMBIO DIAGNOSTICS, INC. (0001092662) (Filer)

      5/3/23 12:15:15 AM ET
      $CEMI
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form EFFECT filed by Chembio Diagnostics Inc.

      EFFECT - CHEMBIO DIAGNOSTICS, INC. (0001092662) (Filer)

      5/3/23 12:15:13 AM ET
      $CEMI
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $CEMI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Chembio Diagnostics Inc. (Amendment)

      SC 13D/A - CHEMBIO DIAGNOSTICS, INC. (0001092662) (Subject)

      5/4/23 6:07:59 AM ET
      $CEMI
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13D filed by Chembio Diagnostics Inc.

      SC 13D - CHEMBIO DIAGNOSTICS, INC. (0001092662) (Subject)

      5/1/23 9:21:54 AM ET
      $CEMI
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13D filed by Chembio Diagnostics Inc.

      SC 13D - CHEMBIO DIAGNOSTICS, INC. (0001092662) (Subject)

      4/7/23 5:19:51 PM ET
      $CEMI
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $CEMI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Angelico Paul

      4 - CHEMBIO DIAGNOSTICS, INC. (0001092662) (Issuer)

      5/2/23 4:39:52 PM ET
      $CEMI
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 4 filed by Acheson David

      4 - CHEMBIO DIAGNOSTICS, INC. (0001092662) (Issuer)

      5/1/23 9:03:38 PM ET
      $CEMI
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 4 filed by Eberly Richard

      4 - CHEMBIO DIAGNOSTICS, INC. (0001092662) (Issuer)

      5/1/23 9:03:36 PM ET
      $CEMI
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care